Preclinical Blood Pressure measurements

In our recent SPS 2022 hosted session, we discussed the Translational Assessment of Pressor Effects of Drugs with Dr.Christine Garnett (FDA), Dr.Todd Wisialowski (Pfizer) and Dr.Brian Roche (Charles River).

They presented a short overview of their work before participating in the discussion and sharing their expertise on pressure liabilities in drug development.

This document summarizes some of the key points that were explored and offers additional resources and considerations for IND-enabling studies. It will first explore clinical drivers for blood pressure assessment before reviewing preclinical translational considerations

 

By browsing this website, you accept the use of cookies for statistical purposes.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are set through our site by our advertising partners.

We use Adwords to track our Conversions through Google Clicks.

We use Hubspot to monitor our traffic and to help us AB test new features.